Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR

达拉图穆马 硼替佐米 地塞米松 多发性骨髓瘤 危险系数 来那度胺 胃肠病学 人口 医学 内科学 置信区间 外科 环境卫生
作者
María‐Victoria Mateos,Pieter Sonneveld,Vânia Hungria,Ajay K. Nooka,Jane Estell,Wolney Barreto,Paolo Corradini,Chang‐Ki Min,Eva Medvedova,Katja Weisel,Christopher Chiu,Jordan M. Schecter,Himal Amin,Xiang Qin,Jon Ukropec,Rachel Kobos,Andrew Spencer
出处
期刊:Clinical Lymphoma, Myeloma & Leukemia [Elsevier BV]
卷期号:20 (8): 509-518 被引量:128
标识
DOI:10.1016/j.clml.2019.09.623
摘要

BackgroundIn the phase III CASTOR study in relapsed or refractory multiple myeloma, daratumumab, bortezomib, and dexamethasone (D-Vd) demonstrated significant clinical benefit versus Vd alone. Outcomes after 40.0 months of median follow-up are discussed.Patients and MethodsEligible patients had received ≥ 1 line of treatment and were administered bortezomib (1.3 mg/m2) and dexamethasone (20 mg) for 8 cycles with or without daratumumab (16 mg/kg) until disease progression.ResultsOf 498 patients in the intent-to-treat (ITT) population (D-Vd, n = 251; Vd, n = 247), 47% had 1 prior line of treatment (1PL; D-Vd, n = 122; Vd, n = 113). Median progression-free survival (PFS) was significantly prolonged with D-Vd versus Vd in the ITT population (16.7 vs. 7.1 months; hazard ratio [HR], 0.31; 95% confidence interval [CI], 0.25-0.40; P < .0001) and the 1PL subgroup (27.0 vs. 7.9 months; HR, 0.22; 95% CI, 0.15-0.32; P < .0001). In lenalidomide-refractory patients, the median PFS was 7.8 versus 4.9 months (HR, 0.44; 95% CI, 0.28-0.68; P = .0002) for D-Vd (n = 60) versus Vd (n = 81). Minimal residual disease (MRD)–negativity rates (10−5) were greater with D-Vd versus Vd (ITT: 14% vs. 2%; 1PL: 20% vs. 3%; both P < .0001). PFS2 was significantly prolonged with D-Vd versus Vd (ITT: HR, 0.48; 95% CI, 0.38-0.61; 1PL: HR, 0.35; 95% CI, 0.24-0.51; P < .0001). No new safety concerns were observed.ConclusionAfter 3 years, D-Vd maintained significant benefits in patients with relapsed or refractory multiple myeloma with a consistent safety profile. D-Vd provided the greatest benefit at first relapse and increased MRD-negativity rates.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
3080发布了新的文献求助20
刚刚
拖把粘十发布了新的文献求助10
1秒前
2秒前
3秒前
3秒前
Jasper应助芝士奶盖有点咸采纳,获得10
4秒前
4秒前
liiiii发布了新的文献求助10
5秒前
liiiii发布了新的文献求助10
7秒前
liiiii发布了新的文献求助10
7秒前
JamesPei应助认真跳跳糖采纳,获得10
7秒前
8秒前
liiiii发布了新的文献求助10
8秒前
张雯思发布了新的文献求助10
8秒前
WK完成签到,获得积分10
9秒前
9秒前
Muhammad发布了新的文献求助10
10秒前
FashionBoy应助Karol采纳,获得10
12秒前
Michelangelo_微风完成签到,获得积分10
12秒前
平淡汽车完成签到,获得积分10
12秒前
13秒前
徐徐发布了新的文献求助10
16秒前
共享精神应助优秀的莹采纳,获得10
17秒前
17秒前
17秒前
平淡汽车发布了新的文献求助10
18秒前
18秒前
顾众生发布了新的文献求助10
18秒前
19秒前
情怀应助阿圆采纳,获得10
20秒前
画晴完成签到,获得积分20
20秒前
sc30完成签到,获得积分20
20秒前
LI完成签到,获得积分10
21秒前
22秒前
邓欣怡发布了新的文献求助10
23秒前
slj发布了新的文献求助10
24秒前
赵Zhao完成签到,获得积分10
24秒前
25秒前
sc30发布了新的文献求助20
25秒前
26秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989711
求助须知:如何正确求助?哪些是违规求助? 3531864
关于积分的说明 11255235
捐赠科研通 3270505
什么是DOI,文献DOI怎么找? 1804983
邀请新用户注册赠送积分活动 882157
科研通“疑难数据库(出版商)”最低求助积分说明 809176